Top Links

Articles Related to Pharmacology

Veterinary Considerations for the Theoretical Resurrection of Extinct Species

The de-extinction of the dinosaur is a dubious possibility but its consideration brings forth some issues that are at least worthy of scientific discussion. In this review, we discuss two distinct issues that have implications for a de-extinct species such as a dinosaur: the ability, or lack thereof, to safely sedate a rare and potentially fractious animal capable of harming the veterinary staff tasked with its care; and, disease risks associated with a species that has been extinct for millions of years. To identify potential sedatives, comparative pharmacology will be needed to uncover the links between receptor pharmacology and the desired clinical outcomes of activating established alpha-2 adrenergic, opioid, and benzodiazepine receptors. Specific to disease control, it will be necessary to understand the unique susceptibility of the new species to current diseases as well as predicting their reservoir capacity for potential human and veterinary pandemic diseases. While the topics presented herein are not exhaustive, this review highlights some of the foremost research that should be conducted in order to serve the unique veterinary needs of a de-extinct species using the dinosaur as a paradigm. Addressing these issues should be considered if an intact dinosaur genome becomes available, regardless of the feasibility of dinosaur resurrection.
View complete article: PDF  |  Full-text

Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery

Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.
View complete article: PDF  |  Full-text

Treatments for Atopic Dermatitis

Atopic dermatitis, also known as eczema, affects about 10-20% of children in the UK and about 1-3% of adults [1]. The incidence of atopic dermatitis has increased as much as 3 fold in the past 40 years
View complete article: PDF  |  Full-text  | Digital
 
 


Editorial Board Members Related to Pharmacology

Hong Zhu

Associate Professor
Campbell University School of Osteopathic Medicine
United States

Rathnayake Mudiyanselage Dharmadasa

Senior Deputy Director
Industrial Technology Institute
Sriparakum Mawatha
Sri Lanka

David J. MacEwan

Professor
Department of Molecular & Clinical Pharmacology
Institute of Translational Medicine
University of Liverpool
United Kingdom

Khaldon Bodoor

Associate Professor
Department of Biotechnology and Genetic Engineering
Jordan University of Science and Technology
Jordan

Dilip K. Tosh

Laboratory of Bioorganic Chemistry
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
USA

Louis-Ferdinand

Professor
Department of Pharmaceutical Sciences
Wayne State University
United States

David Paul Richman

Professor
Department of Neurology and Center for Neuroscience
University of California
United States

Marco Weiergraber

Principal Investigator & Group leader
Neuropsychopharmacology
Federal Institute for Drugs and Medical Devices
Germany

Kristian Linnet

Professor
Department of Forensic Medicine
University of Copenhagen
Denmark

Vincenzo Cuomo

Professor
Department of Physiology and Pharmacology
Sapienza University of Rome
Italy
Submit Manuscript